 congress held from June 29 to July 2, 2024){kind=link}
In a significant development for the field of neurology, BrainTale, a medtech spin-off from the Paris Region Greater Hospitals, showcased its latest research at the European Academy of Neurology (EAN) congress held from June 29 to July 2, 2024. The data presented by Vincent Perlbarg, co-founder and scientific director, and Martin Grange, data scientist, revealed the potential of BrainTale’s innovative solution to accurately differentiate Parkinson’s disease (PD) from other neurodegenerative conditions with similar clinical features, such as Multisystem Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).
The challenge of diagnosing Parkinson’s disease, which affects approximately 5 million people globally, remains formidable due to overlapping symptoms with other disorders. BrainTale’s presentation highlighted the promise of its non-invasive and reliable diagnostic tools in addressing this issue. Since its inception, BrainTale has focused on developing accessible, actionable, and clinically validated measurement and prediction tools for patients with brain diseases.
During their oral presentation titled “Differential diagnosis model in parkinsonian syndromes derived from calibrated diffusion tensor imaging,” BrainTale shared findings from a study involving 189 subjects with parkinsonian symptoms across three prospective trials. The study included 92 patients with PD, 45 with MSA, and 42 with PSP. Using automatically processed data to extract diffusion tensor imaging (DTI) parameters, a supervised learning classification model was tested through receiver operating characteristic (ROC) analysis. The results were impressive, with the model achieving a mean area under the ROC curve of 0.87 ± 0.05, a mean specificity of 0.74 ± 0.10, and a mean sensitivity of 0.90 ± 0.07.
These findings underscore the sensitivity of white matter markers provided by BrainTale’s technology in effectively classifying parkinsonian syndromes, particularly in distinguishing PD from MSA and PSP, two conditions often mistaken for Parkinson’s.
“The easy access to diffusion tensor markers in the clinical setting with BrainTale’s platform paves the way for improving differential diagnosis and accelerating treatment development,” remarked Professor Stéphane Lehéricy, a neuroradiologist at Paris Region Greater Hospitals and Director at the Brain Institute. “This technology also enables us to better understand the pathophysiology of different diseases and facilitates patient care in a non-invasive and reliable way,” he added.
BrainTale’s advancements promise to enhance the diagnostic process for Parkinson’s disease, providing a clearer path for treatment and care, and offering hope to millions of patients and healthcare providers worldwide.